Pulmonx (NASDAQ:LUNG) Upgraded to "Hold" at Wall Street Zen

Key Points

• Pulmonx has been upgraded from a "sell" to a "hold" rating by analysts at Wall Street Zen, indicating a more favorable outlook for the stock.
• Multiple analysts have reduced their target prices for Pulmonx, with shares currently trading at around $1.71, significantly below previous targets ranging up to $17.00.
• Institutional investors are actively engaging with the stock, with several firms increasing their stakes, reflecting confidence in the company's potential despite recent challenges.

Wall Street Zen upgraded shares of Pulmonx (NASDAQ:LUNG - Free Report) from a sell rating to a hold rating in a report released on Saturday.

A number of other equities analysts also recently commented on LUNG. Wells Fargo & Company reduced their price objective on shares of Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Lake Street Capital reduced their price target on Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, July 31st. Piper Sandler lowered Pulmonx from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $9.00 to $2.50 in a research report on Thursday, July 31st. Stifel Nicolaus cut their price objective on Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, July 31st. Finally, D. Boral Capital lowered their target price on shares of Pulmonx from $17.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, July 31st. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.66.

Pulmonx Stock Up 4.8%

NASDAQ LUNG traded up $0.08 on Friday, reaching $1.74. The company had a trading volume of 362,490 shares, compared to its average volume of 717,706. The company's fifty day moving average is $2.27 and its 200-day moving average is $4.18. The firm has a market capitalization of $70.91 million, a price-to-earnings ratio of -1.22 and a beta of 0.43. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35. Pulmonx has a 1-year low of $1.47 and a 1-year high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%.The business had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx has set its FY 2025 guidance at EPS. On average, research analysts forecast that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Richard Ferrari sold 8,000 shares of the stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $3.16, for a total value of $25,280.00. Following the transaction, the director directly owned 87,024 shares of the company's stock, valued at $274,995.84. This represents a 8.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 41,896 shares of company stock worth $79,514 over the last three months. Insiders own 6.80% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in Pulmonx by 48.7% during the fourth quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock worth $125,000 after acquiring an additional 6,033 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Pulmonx by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company's stock worth $2,770,000 after purchasing an additional 60,489 shares during the last quarter. Stifel Financial Corp bought a new stake in Pulmonx in the 4th quarter valued at $81,000. Susquehanna Fundamental Investments LLC acquired a new position in Pulmonx in the 4th quarter valued at $417,000. Finally, Tudor Investment Corp ET AL increased its position in Pulmonx by 9.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 149,102 shares of the company's stock worth $1,012,000 after buying an additional 12,282 shares during the period. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.